Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 237-410-6 | CAS number: 13775-53-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Key value for chemical safety assessment
Additional information
In vitro studies
Synthetic cryolite was negative in a gene mutation assay with Salmonella typhimurium tester strains TA1535, TA1537, TA98 and TA100 with and without S-9 mix obtained from Aroclor induced rat livers (Bayer AG, 1988). Doses ranging from 20 to 12,500 μg/plate were tested without toxic effects. The test was conducted in line with OECD guideline 471.
A well-conducted Rat Hepatocyte Primary Culture/DNA Repair Test is available (Pharmakon Research International, 1991a). The highest dose level evaluated in the study was 50 µg/ml as concentrations from 100 µg/ml induced cytotoxicity. Additional levels evaluated were 1, 5 and 10 µg/ml. None of the treated cultures produced mean NNG counts that were substantially greater than the solvent control and the % of cells in repair were less than 10%. Cryolite was considered negative in inducing unscheduled DNA repair in primary hepatocytes under the conditions of this assay. Based on this study, it can be assumed that cryolite does not induce gene mutations in mammalian cells in vitro.
Furthermore, a well-conducted (equivalent protocol compared to relevant OECD guideline) chromosome aberration study is available (Pharmakon Research International, 1991b). Initially, cryolite was evaluated for cytotoxicity in human lymphocyte cultures utilising cell proliferation kinetics and mitotic index (M.I.) as parameters. Cryolite was evaluated at concentrations of 1, 5, 25, 50, 75, 100, 175, 250, 500 and 1000 µg/ml with and without an exogenous metabolic activation system (S9 mix). Concurrent untreated and solvent (HPLC Grade Water) controls were also evaluated. Based on the cytogenetic findings, the concentrations selected for the chromosome aberration assay were 100, 500 and 1000 µg/ml. Human lymphocytes were exposed to three different phases of the cell cycle (G0/G1, 2 and S) after lymphocytic culture initiation. Each set of cultures was harvested at the appropriate scheduled time.
Results of the assay indicated no statistically significant increase in the proportion of aberrant metaphases or total aberrations/cell at any dose level or at any time interval evaluated.
In vivo studies
Inhalation exposure to 4.6 mg/m3 cryolite for 13 weeks was negative in a bone marrow chromosomal aberration test with male Crl:CD BR Sprague-Dawley rats; there was no effect on mitotic activity (Bayer AG, 1997a). This cytogenetic test was run within the 13-week study described in the section on repeated dose toxicity. Increased inorganic fluoride concentrations in urine, bones, and teeth were evident for rats in exposed to 4.6 mg/m3 cryolite in the 90 days inhalation toxicity study (see repeated dose toxicity) showing systemic exposure to cryolite.
Furthermore, in an in vivo bone marrow chromosomal aberration test, male and female Crl:CD BR Sprague-Dawley rats were exposed by snout-only inhalation to 2130 mg/m3cryolite for 6 hours (Huntingdon Life Sciences Ltd., 1997b / Bayer AG, 1997b). Results were negative for male and female animals. Bone marrow cells were sampled after recovery periods of 16, 24 and 48 hours. No clinical signs or mortalities were induced and there was no inhibition of mitotic activities of the target cells. All experimental parts were run in compliance with GLP and according to OECD guideline 475.
Short description of key information:
Cryolite does not induce gene mutations in a bacterial in vitro system. In vitro tests on induction of chromosomal aberrations (human lymphocytes) and unscheduled DNA synthesis (rat hepatocytes) are reported to be negative.
In vivo cryolite was negative in rat bone marrow chromosomal aberration tests after acute and repeated inhalation exposure.
Endpoint Conclusion: No adverse effect observed (negative)
Justification for classification or non-classification
Based on the available data and in accordance with Directive 67/548/EEC and EU Classification, Labeling and Packaging of Substances and Mixtures (CLP) Regulation (EC) No. 1272/2008, classification is not necessary for mutagenicity.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.